Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience

Tzortzaki, Eleni G.; Georgiou, Andreas; Kampas, Dimitrios; Lemessios, Marinos; Markatos, Miltiadis; Adamidi, Tonia; Samara, Katerina D.; Skoula, Georgia; Damianaki, Aggeliki; Schiza, Sophia; Tzanakis, Nikos; Siafakas, Nikolaos M.

doi:10.1016/j.pupt.2011.11.004

Cited by 65 publications

(97 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average age of patients was 54 ± 14 years; the inclusion criteria stated that the register involved over-12 children; however, the precise number of children is, unfortunately, not specified. The results obtained by means of this register provide convincing proof that omalizumab's clinical effectiveness registered previously by means of RCTs is quite reproducible in the normal practice [29]. The clinical monitoring project implemented in Germany involved 195 over-12 patients from 85 centers (in total) [30].…”

Section: Registers Of Allergic Diseasessupporting

confidence: 62%

“…The analysis demonstrated that the rate of asthma exacerbations and emergency care request significantly decrease in the setting of the performed therapy [28]. In Greece the register of patients with BA treated with omalizumab involved 60 patients under long-term clinical monitoring from 4 centers [29]. Therapy effectiveness was evaluated by the standard (by then) criteria (asthma control level and external respiration parameters, baseline therapy dose and number of exacerbations) after 4 months, 1 year and 4 years in comparison with the initial parameters in the real clinical conditions.…”

Section: Registers Of Allergic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Universal information structure as a tool of long-term follow-up monitoring in allergology

Вишнева¹,

Намазова-баранова²,

Antonova³

et al. 2014

PPh

View full text Add to dashboard Cite

Section: Registers Of Allergic Diseasessupporting

confidence: 62%

Section: Registers Of Allergic Diseasesmentioning

confidence: 99%

Universal information structure as a tool of long-term follow-up monitoring in allergology

Вишнева¹,

Намазова-баранова²,

Antonova³

et al. 2014

PPh

View full text Add to dashboard Cite

“…In the INNOVATE trial, a moderate but at the same time statistically significant improvement in forced expiratory volume in 1 sec (FEV 1 ) and morning peak expiratory flow (PEF) from baseline was observed compared to that in placebo group (25). Moreover, in a real-life setting, a significant improvement of FEV 1 was observed after 4 years of omalizumab treatment (31).…”

Section: Lung Functionmentioning

confidence: 98%

Severe Asthma: Anti-IgE or Anti-IL-5?

Bakakos¹,

Loukides²

2015

J Allergy Ther

View full text Add to dashboard Cite

Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced quality of life and poor asthma control as ordinary treatment regimens remain inadequate. Difficulty in managing severe asthma derives partly from the multiple existing phenotypes and our inability to recognise them. Though the exact pathogenetic pathway of severe allergic asthma remains unclear, it is known that numerous inflammatory cells and cytokines are involved, and eosinophils represent a key inflammatory cell mediator. Anti-IgE (omalizumab) and anti-IL-5 (mepolizumab) antibodies are biological agents that interfere in different steps of the Th2 inflammatory cascade and are licensed in severe asthma. Both exhibit a favourable clinical outcome as they reduce exacerbation rate and improve asthma control and quality of life, while mepolizumab also induces an oral steroid sparing effect. Nevertheless, it is still questionable which agent is more suitable in the management of severe allergic asthma since no comparable studies have been conducted. Omalizumab's established effectiveness in clinical practice over a long period is complemented by a beneficial effect on airway remodelling process mediated mainly through its impact on eosinophils and other parameters strongly related to eosinophilic inflammation. However, it is possible that mepolizumab through nearly depleting eosinophils could have a similar effect on airway remodelling. Moreover, to date, markers indicative of the patient population responding to each treatment are unavailable although baseline eosinophils and exacerbation rate in the previous year demonstrate a predictive value regarding anti-IL-5 therapy effectiveness. On the other hand, a better therapeutic response for omalizumab has been observed when low forced expiratory volume in 1 sec, high-dose inhaled corticosteroids and increased IgE concentrations are present. Consequently, conclusions are not yet safe to be drawn based on existing knowledge, and additional research is necessary to unravel the remaining issues for the severe asthmatic population.

show abstract

“…Эффективность терапии оценивалась через 4 мес, 1 год и 4 года по стандартным параметрам -опреде-ление уровня контроля над заболеванием (АСТ-тест), изменение ОФВ 1 , объем базисной терапии и частота обо-стрений. Параметры оценивались в сравнении с показа-телями до начала лечения и через указанный промежуток времени в реальных клинических условиях [27].…”

Section: Noteunclassified

The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry

Вишнёва¹,

Намазова-Баранова²,

Dobrynina³

et al. 2018

Pediatr. farmakol.

View full text Add to dashboard Cite

Пациентские регистры помогают получать не только актуальную информацию об особенностях течения заболева-ний, о безопасности и эффективности используемых медицинских технологий, но и позволяют осуществлять дли-тельное наблюдение за исследуемой группой больных. Цель исследования -проанализировать эффективность и безопасность длительной таргетной терапии омализумабом (более 4 лет) у детей с тяжелой персистирующей неконтролируемой бронхиальной астмой по данным электронной информационной базы данных клинических слу-чаев (регистра). (Me 14 [12;17,5],24]; p=0,0017). Было зафиксировано уменьшение объема ежедневной базисной терапии: до начала терапии средняя доза ингаляционных глюкокорти-костероидов в пересчете на флутиказон составляла 575 мкг/сут (Me 500 [437,5; 750]), через 48 мес -492 мкг/ сут (Me 500 [250; 562,5]; p=0,066); сокращение количества обострений и потребности в применении короткодей-ствующих β 2 -агонистов -с 12 (Me 10,5 [9,75;13,25] [225; 375]. Asthma control test (ACT) before the start of the treatment was 14 points (Me 14 [12;17,5],24]; p=0,0017). The decrease of the amount of the daily therapy was demonstrated. The median dose of the ICS (fluticasone) was 575 mcg/day (Me 500 [437,5; 750]) before the start of the treatment, in 48 mo -492 mcg/day (Me 500 [250; 562,5]; p=0,066). The decrease of the number of exacerbations and the use of SABA from 12 (Me 10,5 [9,75;13,25]

show abstract

Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience

Cited by 65 publications

References 22 publications

Universal information structure as a tool of long-term follow-up monitoring in allergology

Universal information structure as a tool of long-term follow-up monitoring in allergology

Severe Asthma: Anti-IgE or Anti-IL-5?

The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry

Contact Info

Product

Resources

About